Scarica l'app Stockscreener
15.54
8.82%
1.26
Precedente Chiudi:
$14.28
Aprire:
$14.28
Volume 24 ore:
213.41K
Relative Volume:
1.20
Capitalizzazione di mercato:
$567.18M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+7.69%
1M Prestazione:
+6.44%
6M Prestazione:
-3.66%
1 anno Prestazione:
-14.94%
Intervallo 1D:
$14.28
$15.87
Intervallo di 1 settimana:
$13.62
$16.00
Portata 52W:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
99 HIGH STREET, BOSTON
Confronta RAPP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
15.54 | 521.19M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-08 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Iniziato | Jefferies | Buy |
| 2024-07-02 | Iniziato | Stifel | Buy |
| 2024-07-02 | Iniziato | TD Cowen | Buy |
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Will Rapport Therapeutics Inc. rebound enough to break evenFree Reliable Chart-Based Trade Entries - Newser
Chart based exit strategy for Rapport Therapeutics Inc.Momentum Detection with Entry Optimization - Newser
How to manage a losing position in Rapport Therapeutics Inc.Strategy Builder for Growth Focused Traders - Newser
Can Rapport Therapeutics Inc. hit a new high this monthEarly Entry Planner for Swing Candidates - Newser
Published on: 2025-08-12 06:02:16 - Newser
Why Rapport Therapeutics Inc. stock attracts strong analyst attentionSecure Asset Flow and Trend Pattern Analysis - Newser
What momentum shifts mean for Rapport Therapeutics Inc.Reversal Signal Prediction Based on Volume - Newser
Market reaction to Rapport Therapeutics Inc.’s recent newsTrade Safety Matrix for Conservative Traders - Newser
What Fibonacci levels say about Rapport Therapeutics Inc. reboundFree Multi-Bagger Potential Stock Forecast Tools - Newser
Rapport Therapeutics Inc.’s volatility index tracking explainedMarket Downturn Defense Strategy Analysis - Newser
Published on: 2025-08-10 00:05:31 - Newser
Candlestick signals on Rapport Therapeutics Inc. stock todayReal Time Trade Execution Alert Plan - Newser
Chart overlay techniques for tracking Rapport Therapeutics Inc.Short-Term Growth Watch with Signal Prediction - Newser
Comparing Rapport Therapeutics Inc. in custom built stock radarsFree Risk-Adjusted Picks With Exit Strategy - Newser
What is HC Wainwright’s Estimate for RAPP Q2 Earnings? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at HC Wainwright - Defense World
Rapport Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rapport Therapeutics' Q2 2025 Update: RAP-219's Precision Neuroscience Potential and September 2025 Catalyst - AInvest
Rapport (RAPP) Q2 Net Loss Widens 47% - AOL.com
Rapport Therapeutics reports Q2 EPS (75c), consensus (79c) - TipRanks
Rapport Therapeutics sees cash runway through end of 2026 - TipRanks
Rapport Therapeutics Reports Q2 2025 Financials and Business Update. - AInvest
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update - GlobeNewswire
Press Release: Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update - 富途牛牛
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright Initiates Rapport Therapeutics at Buy With $31 Price Target - MarketScreener
Is Rapport Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Community Entry Consensus Trade Ideas - Newser
Bank of New York Mellon Corp Acquires 15,514 Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) - Defense World
How hedge fund analytics apply to Rapport Therapeutics Inc. stockFast Entry Strategy with Price Prediction - Newser
Applying chart zones and confluence areas to Rapport Therapeutics Inc.Free Trade Setups With Clear Risk Limits - Newser
Rapport Therapeutics Inc expected to post a loss of 83 cents a shareEarnings Preview - TradingView
AI Indicators Detect Buy Opportunity in Rapport Therapeutics Inc.Community Verified Stock Suggestions Drive Volume - metal.it
Is Rapport Therapeutics Inc. a good long term investmentFree Advanced Stock Screener Access - Jammu Links News
What institutional investors are buying Rapport Therapeutics Inc. stockUnlock expert insights for smarter investing - Jammu Links News
Is Rapport Therapeutics Inc. a growth stock or a value stockConsistently superior profits - Jammu Links News
Does Rapport Therapeutics Inc. stock perform well during market downturnsUnmatched market performance - Jammu Links News
How does Rapport Therapeutics Inc. generate profit in a changing economyAchieve rapid portfolio growth with expert help - Jammu Links News
What drives Rapport Therapeutics Inc. stock priceMassive wealth growth - Jammu Links News
How Rapport Therapeutics Inc. stock performs during market volatilityAlpha Stock Picks with Chart Confirmation - Newser
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Non sono disponibili dati finanziari per Rapport Therapeutics Inc (RAPP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):